Paul L. Den Exter

Paul L. Den Exter

Auto-generated profile, based on publicly available information

Paul L. Den Exter

Department of Medicine, Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, the Netherlands

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 June 2022 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
PEPaul L. Den Exter
Paul L. Den Exter
SWScott C. Woller
Scott C. Woller
HRHelia Robert-Ebadi
Helia Robert-Ebadi
CMCamila Masias
Camila Masias
PMPierre‐Emmanuel Morange
Pierre‐Emmanuel Morange
FKFrederikus A. Klok
Frederikus A. Klok
Patients with acute venous thromboembolism (VTE) require anticoagulant therapy to prevent recurrent VTE and death, which exposes them to an inherent increased risk of bleeding. Identification of patients at high risk of bleeding, and mitigating this risk, is an essential component of the immediate and long‐term therapeutic management of VTE. The bleeding risk can be estimated by either implicit judgment, weighing individual predictors (clinical variables or biomarkers), or by risk prediction tools developed for this purpose. Management of bleeding risk in clinical practice is, however, far from standardized. International guidelines are contradictory and lack clear and consistent guidance on the optimal management of bleeding risk. This report of the ISTH subcommittee on Predictive and Diagnostic Variables in Thrombotic Disease summarizes the evidence on the prediction of bleeding in VTE patients. We systematically searched the literature and identified 34 original studies evaluating either predictors or risk prediction models for prediction of bleeding risk on anticoagulation in VTE patients. Based on this evidence, we provide recommendations for the standardized management of bleeding risk in VTE patients.

1 April 2017 in Thrombosis Research
Verified
Journal Article
Closed access
IWI.T. Wilts
I.T. Wilts
GGGrégoire Le Gal
Grégoire Le Gal
PEP.L. Den Exter
P.L. Den Exter
JEJ. Van Es
J. Van Es
MCMarc Carrier
Marc Carrier
PKP.W. Kamphuisen
P.W. Kamphuisen

11 May 2023 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Closed access
DVDejvid Veizaj
Dejvid Veizaj
PEPaul L. Den Exter
Paul L. Den Exter
Mettine BosMettine Bos
Mettine Bos

12 July 2024 in European Heart Journal
Verified
Journal Article
Open access
PDF file
DLDieuwke Luijten
Dieuwke Luijten
DDDelphine Douillet
Delphine Douillet
KLKim Luijken
Kim Luijken
CTCecile Tromeur
Cecile Tromeur
APAndrea Penaloza
Andrea Penaloza
FKFrederikus A. Klok
Frederikus A. Klok
Home treatment is considered safe in acute pulmonary embolism (PE) patients selected by a validated triage tool (e.g. simplified PE severity index score or Hestia rule), but there is uncertainty regarding the applicability in underrepresented subgroups. The aim was to evaluate the safety of home treatment by performing an individual patient-level data meta-analysis. Ten prospective cohort studies or randomized controlled trials were identified in a systematic search, totalling 2694 PE patients treated at home (discharged within 24 h) and identified by a predefined triage tool. The 14- and 30-day incidences of all-cause mortality and adverse events (combined endpoint of recurrent venous thromboembolism, major bleeding, and/or all-cause mortality) were evaluated. The relative risk (RR) for 14- and 30-day mortalities and adverse events is calculated in subgroups using a random effects model. The 14- and 30-day mortalities were 0.11% [95% confidence interval (CI) 0.0–0.24, I2 = 0) and 0.30% (95% CI 0.09–0.51, I2 = 0). The 14- and 30-day incidences of adverse events were 0.56% (95% CI 0.28–0.84, I2 = 0) and 1.2% (95% CI 0.79–1.6, I2 = 0). Cancer was associated with increased 30-day mortality [RR 4.9; 95% prediction interval (PI) 2.7–9.1; I2 = 0]. Pre-existing cardiopulmonary disease, abnormal troponin, and abnormal (N-terminal pro–)B-type natriuretic peptide [(NT-pro)BNP] at presentation were associated with an increased incidence of 14-day adverse events [RR 3.5 (95% PI 1.5–7.9, I2 = 0), 2.5 (95% PI 1.3–4.9, I2 = 0), and 3.9 (95% PI 1.6–9.8, I2 = 0), respectively], but not mortality. At 30 days, cancer, abnormal troponin, and abnormal (NT-pro)BNP were associated with an increased incidence of adverse events [RR 2.7 (95% PI 1.4–5.2, I2 = 0), 2.9 (95% PI 1.5–5.7, I2 = 0), and 3.3 (95% PI 1.6–7.1, I2 = 0), respectively]. The incidence of adverse events in home-treated PE patients, selected by a validated triage tool, was very low. Patients with cancer had a three- to five-fold higher incidence of adverse events and death. Patients with increased troponin or (NT-pro)BNP had a three-fold higher risk of adverse events, driven by recurrent venous thromboembolism and bleeding. Safety of home treatment of acute pulmonary embolism in the overall population and clinically relevant patient subgroups. (NT-pro)BNP, (N-terminal pro–)B-type natriuretic peptide; PE, pulmonary embolism; VTE, venous thromboembolism.

8 November 2025 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
KZKonrad van der Zwet
Konrad van der Zwet
AVAmber D.W. de Vos
Amber D.W. de Vos
MCMarjon H. Cnossen
Marjon H. Cnossen
FHFloor C.J.I. Heubel-Moenen
Floor C.J.I. Heubel-Moenen
SSSaskia Schols
Saskia Schols
DKDavid Keeling
David Keeling
Emicizumab provides effective prophylaxis in hemophilia A (HA), but its cost puts a burden on healthcare systems. Pharmacokinetic-pharmacodynamic analyses suggest that emicizumab is effective at lower trough concentrations (Ctrough) than the mean 55 μg/ml reported on conventional dosing. Interim analysis comparing bleeding control during 6 months' of conventional emicizumab dosing versus pharmacokinetic (PK) guided dosing in participants with HA, targeting a Ctrough of 30 ± 5 μg/ml. The DosEmi study (NCT06320626) is an ongoing multicenter, open-label, crossover, Dutch trial. Eligible were participants ≥ 16 years using emicizumab for ≥12 months with good bleeding control (≤2 treated bleeds/6 months, none spontaneous). This planned interim analysis compared 6 months' bleeding on conventional dosing versus PK-guided dosing. Study continuation criteria were ≤15% decrease in the proportion without treated bleeds, maximum 2 spontaneous bleeds overall observed, and <1.0 increase in bleeds/year (ABR). In 26 participants with severe HA PK-guided dosing reduced emicizumab consumption by 39% (range 13-50%). The proportion of participants without treated bleeds was 69% during conventional versus 58% during PK-guided dosing (risk difference +11%, p= 0.254); while the proportion without joint bleeds remained stable 85% vs 88% respectively (risk difference -4%, p=0.500). ABR remained low (0.7 versus 0.9, p=0.132), including one spontaneous muscle bleed (emicizumab concentration 52.5 μg/ml). These interim-results suggest that bleeding control on PK-guided reduced dosing of emicizumab (target Ctrough 30±5 μg/mL) is similar to conventional dosing. All pre-specified criteria for study continuation and inclusion of participants <16 years were met.

26 August 2022 in Research and Practice in Thrombosis and Haemostasis
Verified
Journal Article
Open access
SWScott C. Woller
Scott C. Woller
KWKerstin de Wit
Kerstin de Wit
HRHelia Robert-Ebadi
Helia Robert-Ebadi
CMCamila Masias
Camila Masias
FKFrederikus A. Klok
Frederikus A. Klok
JHJohn‐Bjarne Hansen
John‐Bjarne Hansen
Thrombosis is reported to occur more often among patients with COVID‐19 than otherwise expected in the setting of viral pneumonia and sepsis. Systemic inflammatory biomarkers may be associated with venous thromboembolism (VTE) risk. The ISTH subcommittee on Predictive and Diagnostic Variables in Thrombotic Disease aimed to report the evidence on prognostic biomarkers for VTE in hospitalized patients with COVID‐19. Using a standardized Preferred Reporting Items for Systematic Reviews and Meta‐analysis methodology, we conducted a systematic literature review to identify studies reporting prognostic biomarkers for VTE among hospitalized patients with COVID‐19. Eligible studies included adults hospitalized with COVID‐19 and reported the prognostic associations between any biomarker measured on admission, and the subsequent diagnosis of deep vein thrombosis or pulmonary embolism. Two authors reviewed titles and abstracts, and three authors extracted study data and performed review of bias. Results were displayed descriptively. Meta‐analysis was not possible. From the initial 196 identified studies, full‐text review was performed for 72 studies. Admission D‐dimer levels were associated with VTE during hospitalization in five studies, and elevated platelet count was associated with VTE during hospitalization in one study. The risk of bias ranged from low to high for included studies. Overall, there was a paucity of high‐quality prognostic studies. Studies on other biomarkers did not meet the systematic review inclusion criteria. Admission D‐dimer was associated with VTE diagnosis during hospitalization for COVID‐19; however, prospective validation of this finding is needed to identify optimal D‐dimer thresholds to guide VTE prophylaxis measures.